Health-tech provider sees significant growth and surpasses revenue guidance
- OptimizeRx shares rise 18% with FY23 revenue expected to exceed guidance
- Stock up more than 19% to $15.96 in recent trading
- Shares have increased by 80% in the last three months
- Preliminary 2023 revenue expected to surpass guidance of $68 million to $70 million
- Analysts predict full-year revenue of $68.7 million
- Success with Dynamic Audience Activation Platform
- Expecting new high in Q4 for adjusted Ebitda
Shares of OptimizeRx have risen by 18% as the health-technology provider announces that its full-year revenue for FY23 is expected to surpass guidance. The stock is currently trading at $15.96, reflecting a 19% increase. Over the past three months, shares have surged by an impressive 80%. OptimizeRx, based in Waltham, Mass., specializes in technology that connects healthcare providers and patients. The company anticipates that its preliminary 2023 revenue will exceed the projected range of $68 million to $70 million. Analysts are predicting full-year revenue of $68.7 million, according to FactSet. OptimizeRx attributes its success to the performance of its Dynamic Audience Activation Platform. Additionally, the company expects to achieve a new high in adjusted Ebitda in the fourth quarter.
Public Companies: OptimizeRx (N/A)
Private Companies:
Key People:
Factuality Level: 8
Justification: The article provides specific information about OptimizeRx’s expected full-year revenue exceeding guidance and the stock’s performance. It also mentions the company’s success with its Dynamic Audience Activation Platform and its expectations for adjusted Ebitda in the fourth quarter. The information is supported by the company’s statements and analyst expectations from FactSet.
Noise Level: 3
Justification: The article provides straightforward information about OptimizeRx’s expected revenue and stock performance. It does not contain irrelevant or misleading information, and it stays on topic without diving into unrelated territories. However, it lacks scientific rigor, intellectual honesty, and in-depth analysis of long-term trends or antifragility. It also does not hold powerful people accountable or provide actionable insights or solutions.
Financial Relevance: Yes
Financial Markets Impacted: Shares of OptimizeRx
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to the financial performance of OptimizeRx, a health-technology provider. It discusses the company’s expected full-year revenue exceeding guidance and its success with its Dynamic Audience Activation Platform. There is no mention of an extreme event.
www.marketwatch.com 
